 |
|
Safety and Immunogenicity of High-Dose Edmonston-Zagreb Measles Vaccine in Children With HIV-1 InfectionA Cohort Study in Kigali, Rwanda
Philippe Lepage, MD;
François Dabis, MD, MPH;
Philippe Msellati, MD;
Deo-Gratias Hitimana, MD;
Anna-Maria Stevens, MD, MPH;
Barbara Mukamabano, MD;
Christiaan Van Goethem, MD;
Philippe Van de Perre, MD
Am J Dis Child. 1992;146(5):550-555.
Abstract
#x2022;Objective.
—To compare the reactogenicity and immunogenicity of high-dose Edmonston-Zagreb (EZ) measles vaccine in children with and without human immunodeficiency virus, type 1 (HIV-1), infection.
Design.
—Prospective cohort study.
Setting.
—General pediatric clinic and home visits in Kigali, the capital of Rwanda.
Participants.
—Infants born to HIV-1—seropositive and—seronegative mothers were vaccinated with a 105.0 50% tissue culture infective dose of EZ measles vaccine at 6 months of age. Control visits were made 10 and 14 days later to monitor local and general reactions. Measles serum antibodies were measured by an enzyme-linked immunosorbent assay technique at birth and at 6 and 9 months of age. Three groups were compared: infected children (n=43), uninfected children born to seropositive mothers (n = 135), and uninfected children born to seronegative mothers (n=194).
Results.
#x2014;Three hundred twenty-three children (86.8%) were available for the reactogenicity study. No statistically significant difference between the three groups was found in the occurrence of minor adverse reactions. No severe adverse reaction was observed. One hundred ninety children (51.1%) were available for the immunogenicity study. The percentage of infants negative for measles antibody at 6 months was significantly higher (P=.021) in HIV-infected children (85%) and in uninfected children born to seropositive mothers (90%) than in uninfected children born to seronegative mothers (75%). The overall seroconversion rate at 9 months was 90% (95% confidence interval, 85.7% to 94.3%), without any statistically significant difference between the three groups.
Conclusion.
—High-dose EZ vaccine administered at 6 months of age is safe and highly immunogenic in both HIV-infected and uninfected children.
(AJDC. 1992;146:550-555)
Author Affiliations
From the Department of Pediatrics, Centre Hospitalier de Kigali, Rwanda (Drs Lepage, Hitimana, Stevens, Mukamabano, and Van Goethem); Institut National de la Santé et de la Recherche Médicale, University of Bordeaux II, Bordeaux, France (Drs Dabis and Msellati); and the AIDS Reference Laboratory, National AIDS Control Program, Kigali (Dr Van de Perre).
Footnotes
Accepted for publication October 20, 1991.
Presented in part at the Seventh International Conference on AIDS, Florence, Italy, June 19, 1991.
Reprint requests to 12, rue de la Taille Cuvelier, 7000 Mons, Belgium (Dr Lepage).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Neonatal Measles Immunity in Rural Kenya: The Influence of HIV and Placental Malaria Infections on Placental Transfer of Antibodies and Levels of Antibody in Maternal and Cord Serum Samples
Scott et al.
The Journal of Infectious Disease 2005;191:1854-1860.
ABSTRACT
| FULL TEXT
Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence
Davies and Woo
Rheumatology (Oxford) 2002;41:937-941.
ABSTRACT
| FULL TEXT
Morbidity Among Human Immunodeficiency Virus-1-Infected and -Uninfected African Children
Taha et al.
Pediatrics 2000;106:e77-e77.
ABSTRACT
| FULL TEXT
Natural History of Human Immunodefiency Virus Type 1 Infection in Children: A Five-Year Prospective Study in Rwanda
Spira et al.
Pediatrics 1999;104:e56-e56.
ABSTRACT
| FULL TEXT
|
